Spinocerebellar Ataxia Panel
GTR Test Accession: Help GTR000597424.1
CAP
INHERITED DISEASENERVOUS SYSTEMPSYCHIATRIC ... View more
Registered in GTR: 2022-03-24
Last annual review date for the lab: 2024-05-28 LinkOut
At a Glance
Diagnosis
Azorean disease; Spinocerebellar ataxia 7; Spinocerebellar ataxia type 1 more...
Genes (5): Help
ATXN1 (6p22.3); ATXN2 (12q24.12); ATXN3 (14q32.12); ATXN7 (3p14.1); CACNA1A (19p13.13)
Molecular Genetics - Targeted variant analysis: Trinucleotide repeat by PCR or Southern Blot
Individuals with clinical features of spinocerebellar ataxia
Not provided
Establish or confirm diagnosis
Ordering Information
Offered by: Help
Test short name: Help
SCAP
Specimen Source: Help
Who can order: Help
  • Genetic Counselor
  • Health Care Provider
  • Licensed Dentist
  • Licensed Physician
  • Nurse Practitioner
  • Physician Assistant
  • Public Health Mandate
  • Registered Nurse
Test Order Code: Help
Lab contact: Help
Emily Lauer, MS, CGC, Certified Genetic counselor, CGC, Genetic Counselor
gcmolgen@mayo.edu
1-800-533-1710
Contact Policy: Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order: Help
https://www.mayocliniclabs.com/test-catalog/overview/609505#Specimen
Order URL
Test development: Help
Test developed by laboratory (no manufacturer test name)
Informed consent required: Help
Based on applicable state law
Pre-test genetic counseling required: Help
No
Post-test genetic counseling required: Help
No
Recommended fields not provided:
Conditions Help
Total conditions: 5
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 5
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 1
Method Category Help
Test method Help
Instrument
Targeted variant analysis
Trinucleotide repeat by PCR or Southern Blot
Applied Biosystems 3730 capillary sequencing instrument
Clinical Information
Test purpose: Help
Diagnosis
Clinical utility: Help
Establish or confirm diagnosis
View citations (1)
  • Spinocerebellar ataxias. Soong BW, et al. Handb Clin Neurol. 2018;155:143-174. doi:10.1016/B978-0-444-64189-2.00010-X. PMID: 29891056.

Target population: Help
Individuals with clinical features of spinocerebellar ataxia
View citations (1)
  • Spinocerebellar ataxias. Soong BW, et al. Handb Clin Neurol. 2018;155:143-174. doi:10.1016/B978-0-444-64189-2.00010-X. PMID: 29891056.
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS? Help
All detected variants are evaluated according to the most recent American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) recommendations. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Are family members with defined clinical status recruited to assess significance of VUS without charge? Help
Decline to answer. Contact lab for details

Will the lab re-contact the ordering physician if variant interpretation changes? Help
No. The laboratory encourages health care providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time.
Research:
Is research allowed on the sample after clinical testing is complete? Help
Research testing is only performed under IRB approved protocol with an opt-out policy in place.
Recommended fields not provided:
Technical Information
Test Procedure: Help
A polymerase-chain reaction-based assay is used to amplify across the region of the ATXN1, ATXN2, ATXN3, CACNA1A, or ATXN7 genes containing CAG repeats. Additionally, testing assesses for CAT trinucleotides that interrupt the CAG repeat tract within the ATXN1 gene.(Unpublished Mayo method)
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
Analytical sensitivity, specificity, and accuracy are ≥ 99%
Assay limitations: Help
For predictive testing, it is important to first document the presence of a cytosine-adenine-guanine (CAG)-repeat expansion in an affected family member to confirm that the repeat expansion is the underlying mechanism of disease in the family. It is strongly recommended that patients undergoing predictive testing receive genetic counseling both prior … View more
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
Yes

Method used for proficiency testing: Help
Formal PT program

PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
VUS:
Software used to interpret novel variations Help
Variants may be analyzed using any combination of the following: Alamut, REVEL, Polyphen-2, SIFT, AGVGD, MutationTaster, SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, gene-specific online databases, ISCA, UCSC Genome Browser

Laboratory's policy on reporting novel variations Help
All novel variants and copy number variants are evaluated for potential pathogenicity and included in the written report, accordingly.
Recommended fields not provided:
Regulatory Approval
FDA Review: Help
Category: FDA exercises enforcement discretion
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.